April 2021 PMID 33845462

Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Margaret A Tempero, Mokenge P Malafa, Mahmoud Al-Hawary, Stephen W Behrman, Al B Benson, Dana B Cardin, E Gabriela Chiorean, Vincent Chung, Brian Czito, Marco Del Chiaro, Mary Dillhoff, Timothy R Donahue, Efrat Dotan, Cristina R Ferrone, Christos Fountzilas

Mentions

9
Peak: 2 in Apr 2021
across 3 sources since Apr 2021

Extended reach

8,212
potential audience

Total likes

12

Video views

7,005

Mentions per month

Apr 2021 – Jun 2025

Where it's discussed

  • YouTube4 videos
  • News3 articles
  • X / Twitter2 posts

AI synopsis

What people are saying

The social discussions mainly focus on the article's existence and significance, with phrases like 'new article' and hashtags indicating awareness but not deep engagement. The tone is neutral, emphasizing recognition rather than critique or detailed analysis, which aligns with moderate scores across all dimensions.

AgreementModerate agreement

Most discussions acknowledge the importance of the updated guidelines, showing moderate support rather than outright praise.

InterestModerate interest

The posts reflect a basic interest in the article's relevance to pancreatic cancer treatment but lack enthusiasm or detailed critique.

EngagementModerate engagement

Participants seem to passively acknowledge the publication, with minimal deeper analysis or discussion of specific content.

ImpactModerate impact

The conversations suggest that the article is seen as somewhat influential but not critically transformative within the community.

Abstract in brief

  • Pancreatic adenocarcinoma is a leading cause of cancer-related death in the U.S., often diagnosed at an advanced stage, which complicates treatment.
  • The NCCN guidelines offer detailed recommendations for diagnosing, evaluating, treating, and following up with pancreatic cancer patients, with recent updates aligning with new treatment advancements.
  • The focus is on systemic therapies for patients with locally advanced or metastatic pancreatic cancer, including emerging targeted treatments aimed at improving survival rates.]

Top posts

Most liked on X and Bluesky
Paperbirds_Oncology
@PaperbirdsO · X

New article: Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology https://t.co/BBmt4UBBre #pancreaticcancer #oncology https://t.co/wqLd0fQ6xq

Apr 13, 2021 · 1 like · 1 share · 891 followers View post →
Seiichi Mori
@seiichi_mori · X

RT @PaperbirdsO: New article: Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology https://t.co/BBmt4UB…

Apr 13, 2021 · 1 share · 313 followers View post →

All mentions

Seiichi Mori
@seiichi_mori · X

RT @PaperbirdsO: New article: Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology https://t.co/BBmt4UB…

Apr 13, 2021 · 1 share · 313 followers View post →
Paperbirds_Oncology
@PaperbirdsO · X

New article: Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology https://t.co/BBmt4UBBre #pancreaticcancer #oncology https://t.co/wqLd0fQ6xq

Apr 13, 2021 · 1 like · 1 share · 891 followers View post →